Antibodies to α-Gal and COVID-19

Versión preprint disponible en: http://hdl.handle.net/10261/216781The coronavirus disease 19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has affected millions of people worldwide. The characterization of the immunological mechanisms involved in disease symptomatology and protective response is important to advance in disease control and prevention. Humans evolved by losing the capacity to synthesize the glycan Galα1‐3Galβ1‐(3)4GlcNAc‐R (α‐Gal), which resulted in the development of a protective response against pathogenic viruses and other microorganisms containing this modification on membrane proteins mediated by anti‐α‐Gal IgM/IgG antibodies produced in response to bacterial microbiota. In addition to anti‐α‐Gal antibody‐mediated pathogen opsonization, this glycan induces various immune mechanisms that have shown protection in animal models against infectious diseases without inflammatory responses. In this study, we hypothesized that the immune response to α‐Gal may contribute to the control of COVID‐19. To address this hypothesis, we characterized the antibody response to α‐Gal in patients at different stages of COVID‐19 and in comparison with healthy control individuals. The results showed that while the inflammatory response and the anti‐SARS‐CoV‐2 (Spike) IgG antibody titers increased, reduction in anti‐α‐Gal IgE, IgM and IgG antibody titers and alteration of anti‐α‐Gal antibody isotype composition correlated with COVID‐19 severity. The results suggested that the inhibition of the α‐Gal‐induced immune response may translate into more aggressive viremia and severe disease inflammatory symptoms. These results support the proposal of developing interventions such as probiotics based on commensal bacteria with α‐Gal epitopes to modify the microbiota and increase the α‐Gal‐induced protective immune response and reduce the severity of COVID‐19.This work was partially supported by the Consejería de Educación, Cultura y Deportes, JCCM, Spain, project CCM17-PIC-036 (SBPLY/17/180501/000185). We acknowledge the University of Castilla La Mancha (UCLM, Spain) support to Grupo SaBio. MC was funded by the Ministerio de Ciencia, Innovación y Universidades, Spain (grant FJC-2018-038277-I). IGFM was supported by the UCLM. MV was supported by the UCLM and the Fondo Europeo de Desarrollo Regional, FEDER, EU.Peer reviewe